TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06652958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VH4527079
Description: VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VH4527079
Description: VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VH4527079
Description: VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VH4527079
Description: VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VH4527079
Description: VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VH4527079
Description: VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VH4527079
Description: VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VH4527079
Description: VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VH4527079
Description: VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
Study: NCT03434548

Intervention type: RADIATION
Intervention: PET imaging
Description: PET imaging Radiation: Radioligand \[¹¹C\]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain.~PET imaging Radiation: Radioligand \[¹¹C\]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain.

Intervention type: OTHER
Intervention: Multi-modal MRI imaging
Description: Multi-modal MRI imaging

Intervention type: OTHER
Intervention: Multi-modal MRI imaging
Description: Multi-modal MRI imaging
Study: NCT05697341

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-Mini-PCNL
Description: treatment to extract or disintegrate renal stones

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stented SWL
Description: treatment to disintegrate renal stones in the presence of a JJ
Study: NCT06039995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive Oral Care
Description: The intervention mentioned in this study involves a combination of oral care strategies for patients in the intervention group. These strategies include:~Chlorhexidine Mouthwash: Patients in the intervention group will receive Chlorhexidine mouthwash. Chlorhexidine is known for its effectiveness in maintaining oral hygiene.~Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.~Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.~These interventions aim to enhance oral care beyond traditional methods, potentially reducing the risk of Ventilator-Associated Pneumonia (VAP) and improving overall patient outcomes in the intensive care unit (ICU).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Oral Care
Description: In the control arm, patients receive the intervention known as Traditional Oral Care. This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Tooth Brushing using 0.2% Chlorhexidine
Description: Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moisturizing Gel
Description: Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral care using Cotton swab dipped in 0.2% Chlorhexidine
Description: This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene
Study: NCT05820282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Description: Participants are asked to choose from a list of strategies for increasing delivery of behaviour change interventions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Participants are asked to identify situations and solutions and place a tick next to each one they think would be useful to them. Therefore, participants in the control condition are not asked to form implementation intentions.
Study: NCT05404048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 89Zr-atezolizumab PET-imaging
Description: 89Zr-atezolizumab tracer injection + PET/CT-scan
Study: NCT06713330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFLX crown
Description: Device: BioFLX crown

Intervention type: DEVICE
Group type: OTHER
Intervention: 3M Stainless Steel Crown
Description: 3M Stainless Steel Crown
Study: NCT06726486

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Atémpero
Description: A complete hyperproteic and hypercaloric diet with a mixture of fibres enriched in omega 3, L-arginine and nucleotides (which provides vitamin C and Zinc) was administered.
Study: NCT05580250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally.
Study: NCT05832346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter yoga programme
Description: Intervention for intervention group:~This is a 4-week laughter yoga programme (8 sessions) to help adolescents with intellectual and physical disabilities bring more happiness, laughter and joy to promote their mental health status. As laughter yoga therapy can reduce people's levels of stress, anxiety, depression, loneliness, strengthen the immune system and keep the mind positive. Each laughter yoga session will last for 15 minutes and in total there will be 8 sessions for four weeks (two sessions per week). Each laughter yoga session consists of hand clapping warming-up exercise, followed by deep breathing exercise, childlike playfulness exercise, and then laughter exercise. The intervention group also receives routine care provided by special school.
Study: NCT06188442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DoxyODPrEP
Description: Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DoxyPEP
Description: Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.
Study: NCT04813770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory-based messages
Description: COVID-19 vaccination information structured to address vaccination necessity and concerns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General messages
Description: General messages about the COVID-19 virus and the vaccination programme.
Study: NCT05548023

Intervention type: DEVICE
Group type: OTHER
Intervention: The AngioliteTM Durable Fluoroacrylate Polymer-based Sirolimus-Eluting Stent
Description: The Angiolite stent is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design and a high overexpansion capacity that might overcomes some of these challenges in LMCA PCI. The ANGIOLITE randomized trial confirmed the non-inferiority of the Angiolite stent against the conventional DES
Study: NCT06146530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The intervention consists of 7 sessions of CBT for the treatment of GAD. Each session contains a range of information and tasks/exercises to help the user understand the condition of GAD, the treatment approach, and how it will be applicable to them. The intervention is based on an evidence-based treatment protocol; hence the sessions will flow from one to the other and the user will complete the sessions in a progressive direction. However, they can repeat a session before going on to the next session. Once all sessions have been completed, the user can go back over any of the sessions. There are anxiety management exercises, which the user can go to whenever they wish. There are also a therapy reflection journal and self-care resources including further anxiety management techniques, resources, and podcasts that the user will have access to whenever they want.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: The intervention consists of 7 sessions of CBT for the treatment of GAD. Each session contains a range of information and tasks/exercises to help the user understand the condition of GAD, the treatment approach, and how it will be applicable to them. The intervention is based on an evidence-based treatment protocol; hence the sessions will flow from one to the other and the user will complete the sessions in a progressive direction. However, they can repeat a session before going on to the next session. Once all sessions have been completed, the user can go back over any of the sessions. There are anxiety management exercises, which the user can go to whenever they wish. There are also a therapy reflection journal and self-care resources including further anxiety management techniques, resources, and podcasts that the user will have access to whenever they want.
Study: NCT06484608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic Saline with Dextrose
Description: This clinical trial involves two interventions for maintaining fluid therapy in neonates post-surgery. The first intervention, isotonic saline with dextrose, involves administering 0.9% saline solution combined with 5% dextrose. This isotonic solution aims to maintain serum sodium levels within the normal range and minimize the risk of hyponatremia and hypernatremia in postoperative neonates. The second intervention, hypotonic saline with dextrose, involves administering 0.45% saline solution combined with 5% dextrose. This hypotonic solution is being compared to the isotonic solution to evaluate its effectiveness in maintaining electrolyte balance.
Study: NCT06726486

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Description: A complete high-protein and high-calorie diet with mixed fibre was administered.
Study: NCT06725394

Intervention type: OTHER
Intervention: Filling out the survey
Description: Data were collected using an information form, the Smartphone Addiction Scale-Short Version (SAS-SV), the Perceived Stress Scale (PSS-10), and the Neck Disability Index (NDI).
Study: NCT06484608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic Saline with Dextrose
Description: This clinical trial involves two interventions for maintaining fluid therapy in neonates post-surgery. The first intervention, isotonic saline with dextrose, involves administering 0.9% saline solution combined with 5% dextrose. This isotonic solution aims to maintain serum sodium levels within the normal range and minimize the risk of hyponatremia and hypernatremia in postoperative neonates. The second intervention, hypotonic saline with dextrose, involves administering 0.45% saline solution combined with 5% dextrose. This hypotonic solution is being compared to the isotonic solution to evaluate its effectiveness in maintaining electrolyte balance.
Study: NCT04925011

Intervention type: DRUG
Group type: OTHER
Intervention: Roxadustat
Description: Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
Study: NCT05248516

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Simplified dose of ready-to-use therapeutic food (RUTF)
Description: In the simplified arm all children receive the same dose: 1 sachet of RUTF/day. This until discharge from treatment.~Recovery from treatment will be defined as WAZ\>= -3 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose of ready-to-use therapeutic food (RUTF)
Description: In the standard arm, children will receive different doses of RUTF depending on their WHZ category and weight.~1. children with a WHZ\<-3 will receive the equivalent of 200kcal/kg/d of RUTF until discharge.~2. children with a WHZ between -3 and -2 will receive 1 sachet (500kcal) of RUTF per day until discharge.~3. children with a WHZ\>=-2 will receive no nutritional treatment.~Recovery from treatment will be defined as WHZ\>= -2 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: No nutritional treatment
Description: no nutritional treatment will be provided to children in the control arm.
Study: NCT05233566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: NMDA antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: IV fluid acting as a placebo
Study: NCT06416865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-C52L, AJU-C52
Description: AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks.~AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C52R1L, C52R1M
Description: C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks.~C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks.
Study: NCT06075680

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical Periodontal Treatment
Description: The primary goal of nonsurgical periodontal therapy is to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and result in improvement in the clinical signs and symptoms of active disease

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical Periodontal Treatment
Description: The primary goal of nonsurgical periodontal therapy is to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and result in improvement in the clinical signs and symptoms of active disease
Study: NCT05321394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotrovimab
Description: Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tixagevimab Cilgavimab
Description: 2 subsequent injections:~1. tixagevimab 300mg/3mL (100mg/mL)~2. cilgavimab 300mg/3mL (100mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir Ritonavir
Description: 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together twice daily for 5 days
Study: NCT05325463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional lung recruitment
Description: The recruitment maneuver will be performed by pressure controlled mode maintaining a steady airway pressure of 15 cmH2O, with 5 cmH2O increments in positive end-expiratory pressure (PEEP) until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 sec. The peak airway pressure will be maintained for 10 sec or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound- guided lung recruitment
Description: The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area was visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit was 40 cmH2O.
Study: NCT04952194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stalevo
Description: The dose of Stalevo initially ranges from (Levodopa/Carbidopa/Entacapone) 50/12.5/200 mg 3 times a day to a target dose of 100/25/200 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa and Levodopa Controlled Release Tablets
Description: The dose of Carbidopa and Levodopa Controlled Release Tablets initially ranges from (Levodopa/Carbidopa) 50/12.5mg 3 times a day to a target dose of 100/25 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
Study: NCT06000202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fotona Dynamis Er:YAG Laser System
Description: The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 21 days. She receives 3 sessions, in total. Each session consists of application of PS03 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 6 passes followed by R11 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 3 passes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Er:YAG laser is applied with sham handpiece.
Study: NCT05612581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection
Study: NCT06076317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine session
Description: The content of telemedicine session is semi-standardized and includes: (1) evaluation of the tolerance and efficacy of drug treatment; (2) evaluation of depressive symptoms (PHQ9 scale); (3) identification of the daily difficulties; (4 ) personalized advice and orientation towards appropriate care pathways. Among the personalized advice, investigators will use the digital tools available to maintain remission, psychoeducation and monitoring tools (for example, application to learn mindfulness meditation, conversational chatbot coupled with artificial intelligence, etc.). Support on the use of these tools can be provided during telemedicine sessions.
Study: NCT04966702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole Pill
Description: Using a MDA approach, fieldworkers will administer albendazole using directly observed treatment methodology to participants
Study: NCT05612581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study: NCT06726239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises
Description: The aim of relaxation exercises is for individuals to understand the difference between tension and relaxation and to be able to relax themselves in situations of tension. Relaxation exercises are performed with light music in the background and instructions for relaxation exercises so that patients can focus mentally. The progressive relaxation technique involves voluntary stretching and relaxation of human muscle groups (muscle groups starting with the hand and ending with the foot) (5-10 seconds) 1 repetition for each muscle group. The total duration of the exercises is 20 minutes. The instructions and exercise steps in the Turkish Psychologists Association Publications (TPDY, 2010) Relaxation Exercises CD given to the patient during the exercise will be followed.
Study: NCT06725355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-R00002
Description: Single administration of IN-R00002 60mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-R00002
Description: Single administration of IN-R00002 60mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-G00002
Description: Single administration of IN-G00002 60mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-G00002
Description: Single administration of IN-G00002 60mg
Study: NCT06725485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose Lidocaine
Description: Low-dose lidocaine infusion 10-30 mcg/kg/min administered within 1 hour of ICU admission.